Skip to content
Menu

Kamada Ltd. KMDA

Full chart Compare
Set alert

Price alert · KMDA

All alert types
7.74 USD -0.09 (-1.15%)

Regular-session close

7.74 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

7.72 Day range 7.97
6.68 52-week range 9.31
YTD
+9.63%
1 year
+15.87%

 

No chart data for this range yet.
Market cap
446.85M
Revenue (ttm)
154.57M
Profit margin
9.75%
EPS (ttm)
0.38
Shares out
57.49M
P/E ratio
20.37
Forward P/E
19.52
YTD return
+9.63%
1-year return
+15.87%
Volume
84.31K
Avg volume
122.31K
Open
7.73
Previous close
7.83
Day's range
7.72 – 7.97
52-week range
6.68 – 9.31
Beta
0.20
Price target
14.67 (+89.5%)
50-day average
5.77

Key statistics

200-day average
5.52
Enterprise value
276.22M
Price / sales
2.33
Price / book
1.43
Revenue growth
13.40%
Free cash flow
-7.77M
Total cash
56.55M
Total debt
8.56M
Return on equity
7.04%
Short % of float
0.09%

Fundamental scorecard

19 of 25 checks passed on KMDA’s reported financials

ValueGrowthProfitabilityHealthDividend

19of 25 checks passed

  • Value 3 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KMDA Revenue — quarterly 52.03M
KMDA Net income — quarterly 7.99M
KMDA EPS — quarterly 0.14

Earnings

KMDA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.070.070.000.00%
Aug 14, 2024Jun 1, 20240.060.08+0.02+33.33%
May 8, 2024Mar 1, 20240.060.04-0.02-33.33%
Mar 6, 2024Dec 1, 20230.050.09+0.04+80.00%
Nov 13, 2023Sep 1, 20230.030.06+0.03+100.00%
Aug 16, 2023Jun 1, 20230.020.04+0.02+100.00%

Upgrades / downgrades

KMDA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Aug 15, 2024HC Wainwright & Co.reitBuyBuy
Jul 3, 2024Stifelinit—Buy
May 9, 2024HC Wainwright & Co.reitBuyBuy
Mar 7, 2024HC Wainwright & Co.reitBuyBuy
Nov 14, 2023HC Wainwright & Co.reitBuyBuy

About Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Israel
Website
kamada.com

News

Your note

Sign in to keep a note on KMDA — it syncs with the Stock Master app.

Institution ownership

KMDA institution ownership
Holder% heldSharesValueReported
Phoenix Holdings Ltd.3.19%1,832,95211.09MSep 29, 2024
Vanguard Group Inc2.41%1,384,4308.38MSep 29, 2024
Renaissance Technologies, LLC1.49%856,1065.18MSep 29, 2024
Y.D. More Investments Ltd1.23%709,5514.29MSep 29, 2024
Wells Fargo & Company1.10%629,8843.81MSep 29, 2024
Millennium Management Llc0.62%354,7762.15MSep 29, 2024

Fund ownership

KMDA fund ownership
Holder% heldSharesValueReported
Vanguard International Stock Index-Total Intl Stock Indx1.13%650,2383.93MJul 30, 2024
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund0.54%308,8281.87MSep 29, 2024
DFA Continental Small Company Series0.35%203,0711.23MJul 30, 2024
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index0.26%146,585886.84KJul 30, 2024
DFA International Core Equity Portfolio0.14%78,512475.00KJul 30, 2024
Schwab Strategic Tr-Schwab International Small Cap Equity ETF0.13%73,700445.88KAug 30, 2024